About Trans-3-hydroxy-L-proline dehydratase
Trans-3-hydroxy-L-proline dehydratase (L3HYPDH) is a protein
from Homo sapiens identified by UniProt accession
Q96EM0, 354 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Trans-3-hydroxy-L-proline dehydratase |
| UniProt accession | Q96EM0 |
| Gene | L3HYPDH |
| Organism | Homo sapiens |
| Length | 354 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (17)
Diseases linked to this target (Open Targets).
- substance abuse · score 0.17
- attention deficit hyperactivity disorder · score 0.17
- antisocial behaviour measurement · score 0.17
- monocyte count · score 0.12
- body height · score 0.09
- cortical surface area measurement · score 0.07
- brain volume measurement · score 0.07
- optic disc size measurement · score 0.04
- neurofibrillary tangles measurement · score 0.03
- lower face morphology measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96EM0-F1 | alphafold | PREDICTED | 95.99 | — |
Amino-acid sequence (354 residues)
MESALAVPRL PPHDPGTPVL SVVDMHTGGE PLRIVLAGCP EVSGPTLLAK RRYMRQHLDH VRRRLMFEPR GHRDMYGAVL VPSELPDAHL GVLFLHNEGY SSMCGHAVLA LGRFALDFGL VPAPPAGTRE ARVNIHCPCG LVTAFVACED GRSHGPVRFH SVPAFVLATD LMVDVPGHGK VMVDIAYGGA FYAFVTAEKL GLDICSAKTR DLVDAASAVT EAVKAQFKIN HPDSEDLAFL YGTILTDGKD AYTKEPTTNI CVFADEQVDR SPTGSGVTAR IALQYHKGLL ELNQMRAFKS SATGSVFTGK AVREAKCGDF KAVIVEVSGQ AHYTGTASFI IEDDDPLRDG FLLK
Explore Trans-3-hydroxy-L-proline dehydratase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets